Flex Pharma, Inc. (NASDAQ: FLKS), a clinical-stage biotechnology company that is developing innovative and proprietary treatments for cramps and spasticity associated with severe neurological diseases ...
“We are encouraged by the consistently positive impact of FLX-787 across multiple efficacy endpoints related to cramping and the associated pain, despite the small number of patients completing the ...
Flex Pharma (FLKS-1.4%) initiates a Phase 2 clinical trial, COMMEND, assessing Fast Track-tagged FLX-787 for the treatment of patients with motor neuron disease (MND), primarily amyotrophic lateral ...
Boeing has completed the ultimate load wing-bend test on the 787 static test airframe (ZY997) at its plant in Everett, Washington. The airframer says that it applied loads to replicate 150% of the ...
* Flex Pharma - data from first treatment exposure of 26 subjects showed statistically significant effect in reducing cramp frequency compared to placebo * Phase 2 studies planned for flx-787 to ...
Boeing has completed the ultimate load wing up-bending test on the 787 static test unit, ZY997, at its facility in Everett, Washington. The airframer says that it applied loads to replicate 150% of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results